BioSyent Inc.
Other OTCTotal Valuation
BioSyent Inc. carries a market capitalization of 115.18M, placing it among publicly traded companies globally. Its enterprise value stands at 156.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 115.18M |
| Enterprise Value | 156.09M |
Share Statistics
BioSyent Inc. currently has 11.50M shares outstanding.
| Shares Outstanding | 11.50M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
BioSyent Inc. trades at a trailing price-to-earnings ratio of 17.90. The price-to-sales ratio is 3.52, and the price-to-book ratio stands at 3.73.
| PE Ratio | 17.90 |
| PS Ratio | 3.52 |
| PB Ratio | 3.73 |
| P/TBV Ratio | 8.33 |
| P/FCF Ratio | 12.87 |
| P/OCF Ratio | 12.99 |
Enterprise Valuation
On an enterprise value basis, BioSyent Inc. trades at an EV/EBITDA multiple of 12.06 and an EV/FCF ratio of 12.17. The EV/Sales ratio of 3.39 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 13.21 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.39 |
| EV / EBITDA | 12.06 |
| EV / EBIT | 13.21 |
| EV / FCF | 12.17 |
Financial Position
BioSyent Inc. maintains a current ratio of 1.89, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.66, indicating elevated leverage, while an interest coverage ratio of 190.71 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.89 |
| Quick Ratio | 1.11 |
| Debt / Equity | 11.66 |
| Debt / EBITDA | 0.41 |
| Interest Coverage | 190.71 |
Financial Efficiency
BioSyent Inc. posts a return on equity of 23.25 and a return on invested capital of 19.67.
| Return on Equity (ROE) | 23.25 |
| Return on Assets (ROA) | 17.17 |
| Return on Invested Capital (ROIC) | 19.67 |
| Return on Capital Employed (ROCE) | 21.64 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.35 |
Taxes
Over the trailing twelve months, BioSyent Inc. has paid 3.12M in income taxes, reflecting an effective tax rate of 25.68.
| Income Tax | 3.12M |
| Effective Tax Rate | 25.68 |
Stock Price Statistics
BioSyent Inc.'s stock has gained approximately 18.33137% over the past 52 weeks. The 50-day moving average sits at 10.58, while the 200-day moving average is 9.46.
| Beta (5Y) | N/A |
| 52-Week Price Change | 18.33137% |
| 50-Day Moving Average | 10.58 |
| 200-Day Moving Average | 9.46 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, BioSyent Inc. generated 45.98M in revenue and converted that into 9.04M in net income, yielding earnings per share of 0.79. EBITDA reached 12.94M, while operating income came in at 11.81M.
| Revenue | 45.98M |
| Gross Profit | 34.79M |
| Operating Income | 11.81M |
| Pretax Income | 12.16M |
| Net Income | 9.04M |
| EBITDA | 12.94M |
| EBIT | 11.81M |
| Earnings Per Share (EPS) | 0.79 |
Balance Sheet
BioSyent Inc. holds 10.90M in cash and equivalents against 5.25M in total debt, resulting in a net debt position of -2.65M. Total book value stands at 43.34M, with working capital of 14.76M providing operational flexibility.
| Cash & Cash Equivalents | 10.90M |
| Total Debt | 5.25M |
| Net Debt | -2.65M |
| Equity (Book Value) | 43.34M |
| Book Value Per Share | 3.84 |
| Working Capital | 14.76M |
Cash Flow
BioSyent Inc. produced 12.45M in operating cash flow over the past twelve months. After subtracting -329,033.00 in capital expenditures, free cash flow totaled 12.12M - equivalent to 1.07 per share.
| Operating Cash Flow | 12.45M |
| Capital Expenditures | -329,033.00 |
| Free Cash Flow | 12.12M |
| FCF Per Share | 1.07 |
Margins
BioSyent Inc. operates with a gross margin of 75.67, reflecting its pricing power and cost economics. The operating margin of 25.69 and net profit margin of 19.65 provide insight into operational efficiency.
| Gross Margin | 75.67 |
| Operating Margin | 25.69 |
| Pretax Margin | 26.44 |
| Profit Margin | 19.65 |
| EBITDA Margin | 28.15 |
Dividends & Yields
The company's payout ratio of 25.54 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.20 |
| Dividend Yield | N/A |
| Payout Ratio | 25.54 |
| Shareholder Yield | 0.29 |
| FCF Yield | 7.77 |
Scores
BioSyent Inc. posts an Altman Z-Score of 9.64, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 9.64 |